Whalesbook
The Budgetary Pivot: SEZ Sales Get a Concessional Path
New Delhi – The Serum Institute of India (SII) is navigating a period of regulatory uncertainty following the 2026 Union Budget's announcement to allow manufacturing units within Special Economic Zones (SEZs) to sell goods into the Domestic Tariff Area (DTA) at concessional duty rates. This significant policy shift, presented as a special one-time measure, aims to address concerns over underutilized capacities within SEZs, exacerbated by ongoing global trade disruptions. The finer details, however, remain under deliberation, with specific duty rates yet to be disclosed, pending inter-ministerial consultations between the Finance and Commerce ministries. The lack of clarity leaves companies like SII in a strategic flux, awaiting official guidelines that will dictate the operational and financial impact.
Current SEZ Trade Hurdles and SII's Position
Historically, goods moved from SEZs to the DTA have been treated as imports, attracting standard customs duties based on finished goods' value. This mechanism has historically rendered SEZ products less competitive in the Indian market, leading to an underutilization of manufacturing infrastructure. P.C. Nambiar, a director at SII and head of the Pune Export-Oriented Unit and SEZ Association, highlighted this issue, stating that it has hindered full capacity utilization. For SII, this situation is particularly pertinent as approximately 60% of its supplies are directed to government contracts. Currently, vaccines sold by SII from its SEZ to government entities incur a full basic customs duty of 10%, as these are classified as DTA sales. This levy has created a financial bind, as the Health Ministry, a key customer, has been unwilling to absorb the additional duty, forcing SII to absorb the cost, which impacts its profitability and competitiveness.
Budgetary Concessions and Industry Ramifications
The Finance Minister's proposal to permit these domestic sales at concessional rates, albeit capped by a prescribed proportion of export volumes, signals a recognition of industry demands. The industry had previously advocated for sales to the domestic market on a 'duty-forgone basis' to maintain market viability. While the budget aims to ensure a level playing field for units operating outside SEZs, the exact concessional duty rate will be the deciding factor for the future of SEZ manufacturing for domestic consumption. India hosts over 370 SEZs, which have been integral to export-led growth, contributing significantly to India's exports. The pharmaceutical sector, a cornerstone of India's manufacturing prowess, has also been seeking policy adjustments to navigate complex global trade environments and enhance domestic competitiveness. While SII is a leading vaccine producer, other pharmaceutical entities, including Biocon and Panacea Biotec, operate within similar regulatory frameworks, and will also monitor these developments closely.
Outlook: Navigating Uncertainty Towards Clarity
The immediate outlook for SII and other SEZ-bound manufacturers hinges on the forthcoming clarification of duty rates. Should these rates be substantial, SII may face increased operational costs or be compelled to pass on higher prices for critical vaccines supplied to government immunization programs. Conversely, favorable duty structures could alleviate existing cost pressures and enhance domestic market access. The 'one-time measure' status also suggests a need for ongoing dialogue to ensure sustained policy support and a stable operational environment for the manufacturing sector.